Rare diseases
Investigational molecules
Locations
Recruiting trials first
2 clinical trials in this condition
Study on Water Absorption in the Brain for Adults with Hydrocephalus Using O15-Water
NorwayStudy of Gadobutrol for MRI in Adults with Cerebrospinal Fluid Disorders, Including Hydrocephalus and Brain Tumors
NorwayIn short
Hydrocephalus treatment focuses on managing the dangerous buildup of fluid in the brain, restoring safe pressure levels, and helping patients maintain the best possible quality of life through surgical intervention and careful monitoring.
When someone is diagnosed with hydrocephalus, the main goal of treatment is to reduce the harmful pressure that excess cerebrospinal fluid — the clear liquid that normally cushions the brain and spinal cord — places on delicate brain tissues. Without intervention, this pressure can damage the brain's ability to function properly and, in severe cases, can be life-threatening. Treatment aims to restore the normal flow or absorption of this fluid, allowing the brain to work as it should.
The approach to treatment varies significantly depending on when the condition develops, what caused it, and the patient's age. In babies born with hydrocephalus, early surgical treatment can prevent developmental delays and protect growing brain tissue. In older adults, particularly those with normal pressure hydrocephalus — a form where fluid builds up slowly without dramatically increasing pressure — treatment can help improve walking, bladder control, and memory problems that have gradually worsened over time.
Treatment decisions are guided by medical societies and organizations that have established guidelines based on research and clinical experience. These recommendations help doctors choose the safest and most effective approach for each individual patient. At the same time, researchers continue to explore new therapies through clinical trials, searching for better ways to treat this complex condition and reduce the need for repeated surgeries, which are common with current treatment methods.
The reality is that while hydrocephalus cannot be cured in most cases, it can be managed effectively. Many people with properly treated hydrocephalus live full, active lives, though they require ongoing medical follow-up to ensure their treatment continues to work well. The key is prompt recognition of symptoms and timely intervention, which can make the difference between a good outcome and serious complications.
The primary treatment for hydrocephalus is surgery. Most patients eventually require a surgical procedure to control the fluid buildup, as medical therapy alone is generally not effective for long-term management. However, doctors may use medications as a temporary measure in certain situations, particularly in premature babies with bleeding-related hydrocephalus, to buy time while waiting to see if the brain's natural absorption mechanisms will recover on their own.
When medications are used, they work by decreasing the production of cerebrospinal fluid. The most commonly used drug is acetazolamide, which belongs to a class of medicines called carbonic anhydrase inhibitors. This medication reduces the amount of fluid produced by the choroid plexus — the tissue in the brain's ventricles that makes cerebrospinal fluid. Another medication sometimes used is furosemide, a loop diuretic that helps remove excess fluid from the body and may slightly reduce fluid production in the brain.
The most widely used surgical treatment is shunt placement. A shunt is a thin, flexible tube made of silicone that creates a new pathway for excess cerebrospinal fluid to drain from the brain to another part of the body where it can be safely absorbed. The most common type is a ventriculoperitoneal (VP) shunt, which carries fluid from the brain's ventricles to the abdominal cavity. Inside the shunt system is a valve that controls how quickly fluid drains, preventing it from draining too fast or too slow. Patients can sometimes feel this valve as a small bump under the skin on their scalp.
The shunt surgery is performed by a neurosurgeon — a specialist in brain and nervous system surgery — under general anesthesia, meaning the patient is completely asleep and feels nothing during the procedure. The operation typically takes between one and two hours. The surgeon makes small incisions to place one end of the tube in a brain ventricle and threads the other end under the skin to the abdomen. Most patients stay in the hospital for a few days after surgery to recover and ensure the shunt is working properly. If stitches are used to close the incisions, they may dissolve on their own or need to be removed after several days.
An alternative surgical approach that has become more popular in recent decades is endoscopic third ventriculostomy (ETV). This procedure doesn't involve placing a shunt. Instead, the surgeon uses a small camera called an endoscope to look inside the brain and create a tiny opening in the floor of the third ventricle. This opening allows trapped fluid to flow around the blockage and be absorbed naturally by the brain's surrounding tissues. The procedure is done under general anesthesia and takes about an hour.
ETV is not suitable for everyone. It works best when hydrocephalus is caused by a blockage in the fluid pathways inside the brain, a type called obstructive hydrocephalus or non-communicating hydrocephalus. It's particularly effective for blockages at the narrow channel called the aqueduct of Sylvius that connects different ventricles. However, ETV doesn't work well for communicating hydrocephalus, where the problem is not a blockage but an inability of the brain's surface to absorb fluid properly. Doctors carefully evaluate each patient to determine which surgical approach will work best.
Both shunt surgery and ETV have risks, as all surgeries do. The most significant concern with shunts is that they can malfunction, either by becoming blocked or infected. These complications can happen months or even years after the original surgery and often require additional operations to fix or replace the shunt. Studies show that the risk of shunt failure is particularly high in children. Despite these challenges, shunts remain the most reliable treatment for most forms of hydrocephalus, and many people with shunts live normal, active lives with proper monitoring.
Patients who have shunts or ETV procedures need regular follow-up care throughout their lives. For young children, this usually means visits to the doctor every three to six months in the first two years after surgery, then every year or two as they get older. During these visits, doctors check to make sure the treatment is still working and may order imaging tests like CT scans or MRI scans to look at the size of the ventricles. As children grow, the shunt tubing may need to be lengthened to keep up with their height. Adults also need periodic check-ups, though less frequently than children.
In some specific situations, other surgical options may be considered. If a brain tumor is causing the hydrocephalus by blocking fluid pathways, removing the tumor often resolves the fluid buildup — about 80% of tumor-related hydrocephalus cases are cured this way. For rare cases where the brain is producing too much cerebrospinal fluid, a procedure called choroid plexus coagulation may be performed to reduce fluid production by treating the tissue that makes the fluid. These approaches are less common than shunts or ETV but can be very effective for the right patients.
While surgery remains the cornerstone of hydrocephalus treatment, researchers have been exploring non-surgical approaches for decades, hoping to find ways to prevent the condition from developing or to avoid the need for shunt placement. These investigations include both medications and other innovative strategies, though none have yet proven effective enough to replace surgery for established hydrocephalus.
One area of research focuses on preventing hydrocephalus in babies who have bleeding inside their brain ventricles, a condition called intraventricular hemorrhage that's especially common in premature infants. When blood breaks down in the ventricles, it can interfere with fluid absorption and lead to hydrocephalus. Researchers have tested medications that help dissolve blood clots, hoping to clear the debris before permanent damage occurs. These fibrinolytic drugs break down the fibrin protein that holds clots together. While some early studies showed promise, clinical trials have not yet demonstrated lasting protective effects that would reliably prevent the need for shunts.
Another experimental approach involves medications that reduce scarring and inflammation in the delicate membranes surrounding the brain. After bleeding or infection, these tissues can become thick and scarred, preventing proper fluid absorption. Researchers have investigated drugs that might keep these membranes more flexible and functional, but again, convincing results from rigorous clinical trials have been elusive so far.
Scientists have also explored whether certain medications might protect brain cells from damage while hydrocephalus is developing or after treatment begins. This type of research, called neuroprotection, aims to minimize the harm that excessive fluid pressure causes to neurons and other brain cells. Experimental therapies have included drugs designed to reduce inflammation, limit oxidative damage caused by unstable molecules called free radicals, and improve blood flow to brain tissue. These studies are mostly being conducted in laboratory animals, and much more research is needed before these approaches could be tested in human patients.
One potentially useful application of medication in hydrocephalus care involves using acetazolamide not as a treatment but as a diagnostic test. In adults with suspected normal pressure hydrocephalus, doctors sometimes give a dose of acetazolamide and observe whether the patient's symptoms improve. If walking, thinking, or bladder control gets better after the medication, it suggests the patient would likely benefit from permanent shunt surgery. This test helps doctors predict which patients will respond well to surgical treatment, reducing the risk of performing surgery on someone who wouldn't benefit.
Some research has examined whether manipulating blood flow patterns or the pulsations of cerebrospinal fluid might offer therapeutic benefits. These are complex physiological processes, and altering them safely requires deep understanding of brain mechanics. So far, this work remains in early experimental stages and hasn't led to practical treatments that can be used in patients.
Researchers emphasize that preclinical studies — those done before testing in humans — need to meet stringent scientific standards. The hydrocephalus research community has called for the same rigorous experimental conditions that are required for stroke and brain trauma studies. This includes using proper control groups, randomly assigning experimental subjects to different treatments, and having researchers who don't know which treatment each subject received evaluate the outcomes. These safeguards help ensure that promising findings in the laboratory will actually translate to benefits for patients.
The search for better treatments continues through various research initiatives around the world. Clinical research networks bring together multiple hospitals and medical centers to study hydrocephalus more effectively. These collaborations allow researchers to gather information from larger numbers of patients, which helps identify patterns and test new approaches more rigorously. Patient registries, where individuals with hydrocephalus volunteer to share their medical information for research purposes, also contribute valuable data that can guide future treatment development.
Despite decades of research into medication-based treatments, the reality is that surgical intervention remains far more effective and reliable. The complexity of the brain and the varied causes of hydrocephalus make it challenging to develop a single drug or therapy that works for everyone. However, the ongoing research contributes to better understanding of how the brain produces and absorbs cerebrospinal fluid, which may eventually lead to breakthrough treatments. For now, patients can have confidence that shunt surgery and endoscopic procedures, while imperfect, offer proven ways to manage this serious condition and maintain quality of life.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
